Wegovy® (injection) and decreased appetite

Three regulators, three ways of recording it

All three documents describe semaglutide’s action on appetite. They differ on whether to count it as an adverse reaction. ^[1][2][3]

What a 2.4 mg study measured

In a double-blind trial, 72 adults with obesity received semaglutide increased to 2.4 mg weekly or placebo for 20 weeks. At a lunch where they could eat as much as they liked, the semaglutide group took in 35% less energy. They reported less hunger, more fullness, better control of eating and fewer, weaker cravings, and lost 9.9% of body weight against 0.4% on placebo. ^[4]

The same study looked for slower stomach emptying as an explanation and found no clear evidence of it at week 20. ^[4] The EU summary similarly reports no clinically relevant effect on the rate of gastric emptying with 2.4 mg, probably because the body adapts. ^[2] For most people, then, the smaller appetite reflects signals in the brain rather than food sitting in the stomach. The trial was sponsored by the manufacturer.

Longer term, the EU summary reports that at week 104 of STEP 5, control of cravings and cravings for savoury food favoured semaglutide, while cravings for sweet food showed no clear difference. ^[2]

Why appetite falls

• Supported by the label: GLP-1 receptors sit in brain areas that regulate appetite, and semaglutide reduces calorie intake, most likely through appetite. ^[1] The EU summary adds effects on reward and food choice. ^[2]
• Supported by trial data: nausea, vomiting and fullness are most frequent during dose escalation, ^[1] and on those days appetite can drop further for reasons that have more to do with feeling unwell.
• General medicine: MedlinePlus lists low mood, grief, thyroid, liver and kidney disease and several medicines among other causes of a reduced appetite, so a change that seems out of step with treatment deserves a look. ^[6]

When less food becomes a problem

The Wegovy® documents do not set a lower limit on eating. They do contain warnings that become relevant when intake drops sharply. ^[1]

• Fluids: section 5.5 describes acute kidney injury, mostly in people who became dehydrated after vomiting, diarrhea or nausea, and asks for kidney checks when that happens, especially when starting or increasing the dose. ^[1]
• Gallstones: the label notes that substantial or rapid weight loss can raise the risk, while gallbladder disease was still more common on Wegovy® after allowing for weight loss; gallstones were reported by 1.6% vs 0.7% of adults. ^[1]
• Low blood sugar: in adults with type 2 diabetes, readings below 54 mg/dL were reported by 6.2% on Wegovy® vs 2.5% on placebo, and the risk rises with insulin or a sulfonylurea. ^[1]
• Vitamin B1: six published case reports describe Wernicke’s encephalopathy after semaglutide for obesity, each following prolonged stomach symptoms and substantial weight loss. ^[5] This is rare, but MedlinePlus describes confusion, loss of coordination and eye movement or vision changes as its signs and says they need prompt medical attention. ^[7]

Other things that can take away appetite

If appetite has dropped more than you expected, or for longer, MedlinePlus lists other causes that a clinician may consider ^[6]:

• Sadness, depression or grief; it advises seeking help when low appetite comes with other signs of depression or an eating disorder.
• An underactive thyroid, early pregnancy, dementia or long-term liver, kidney, lung or heart disease.
• Other medicines, including some antibiotics, codeine and morphine, and alcohol or drug use.
• Some cancers, particularly when weight falls without trying.

What official sources suggest

The Medication Guide asks you to drink fluids to lower the chance of dehydration and to report lasting nausea, vomiting or diarrhea to your provider. ^[1] On low-appetite days, drinks are easy to skip, so they are worth planning for separately from meals.

MedlinePlus suggests a diet history: writing down everything you eat and drink over 24 hours or more. ^[6] For appetite loss linked to a medicine, it says to ask your provider about the dose or the medicine rather than stopping on your own. ^[6] The Wegovy® label gives prescribers room to slow the escalation when a step is not tolerated, so that conversation has a clear place in your care. ^[1]

Points specific to Wegovy®

Wegovy® should not be combined with other semaglutide products or other GLP-1 medicines, according to the Medication Guide. ^[1] The Canadian patient information also lists appetite suppressants and weight-loss drugs among medicines to check with your pharmacist or prescriber before taking, because they may raise heart rate. ^[3]

In adolescents, the Canadian monograph reports that 21.7% of those who completed treatment needed two or more consecutive weeks below the 2.4 mg dose because of tolerability. ^[3] If you are caring for a teenager on Wegovy® who is eating very little, that history is useful to their prescriber.

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help